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Membrane fusion entails organelle docking and subsequent mix-
ing of membrane bilayers and luminal compartments. We now
present an in vitro assay of fusion, using yeast vacuoles bearing
domains of either Fos or Jun fused to complementary halves of
-lactamase. Upon fusion, these proteins associate to yield -
lactamase activity. This assay complements the standard fusion
assay (activation of pro-Pho8p in protease-deficient vacuoles by
proteases from pho8 vacuoles). Both the -lactamase and pro-
Pho8p activation assays of fusion show the same long kinetic delay
between SNARE pairing and luminal compartment mixing. Lipid-
mixing occurs rapidly after SNARE pairing but well before aqueous
compartment mixing. These results support a model in which
SNARE pairing leads to rapid hemifusion, followed by slow further
lipid rearrangement and aqueous compartment mixing.
GTPS  hemifusion  membrane fusion  SNARE  yeast vacuole
Yeast vacuole homotypic fusion occurs in several stages.During priming, Sec18p (NSF) and Sec17p disassemble
cis-SNARE complexes, releasing Sec17p and the soluble
SNARE Vam7p. Vacuole tethering is mediated by the Ypt7p
Rab GTPase and its effector complex HOPS. Fusion proteins
and regulatory lipids (diacylglycerol, phosphoinositides, and
ergosterol) are concentrated at a ring-shaped microdomain, the
‘‘vertex ring,’’ surrounding the apposed membranes of docked
vacuoles. During docking, the released Vam7p rebinds to the
vacuole through its affinities for phosphatidylinositol 3-
phosphate (1) and HOPS (2) and participates in the formation
of trans-SNARE complexes between apposed vacuolar mem-
branes. Bilayer fusion around the vertex ring permits lipid and
aqueous compartment mixing. It has been proposed that mem-
brane fusion may require a lipidic ‘‘hemifusion’’ intermediate,
where the closely apposed membrane leaflets are fused and mix,
whereas the distal leaflets and aqueous compartments remain
distinct. Hemifusion has been directly observed with influenza
HA (3–5), either wild-type or with a GPI-anchor in place of its
transmembrane domain (TMD), in a minimal SNARE-driven
liposome fusion system (6, 7) with low levels of wild-type
SNARE proteins or with mutant SNARE proteins with partial
TMDs that span only one bilayer leaflet (6). Hemifusion was also
observed in cell–cell fusion mediated by GPI-anchored SNARE
proteins expressed on the outer surface of the plasma membrane
(8), suggesting that all SNARE-dependent fusion might proceed
by means of hemifusion. A hemifusion intermediate was pro-
posed for yeast vacuole fusion, based on the finding that GTPS
allows lipid mixing while blocking the fusion-dependent activa-
tion of pro-Pho8p (9). The standard in vitro assay of vacuole
fusion measures the proteolytic activation of the inactive pro-
Pho8p (alkaline phosphatase or ALP) by vacuolar proteases
upon content mixing between two populations of vacuoles. One
limitation of this assay is its sensitivity to reagents that inhibit the
activation of ALP. We have therefore developed an in vitro assay
of yeast vacuole fusion in which content mixing between two
vacuole populations is measured by the reconstitution of active
Escherichia coli TEM-1 -lactamase from two complementary
fragments of the enzyme, each contributed from distinct vacuole
populations. This fusion assay, coupled with a lipid mixing assay,
has revealed that docking and lipid mixing are completed long
before luminal contents mix. The kinetic gap between lipid and
content mixing suggests that vacuoles fuse via a hemifusion
intermediate, although we have not directly observed hemifusion
structures.
Results
The standard in vitro vacuole fusion assay requires vacuoles from
two strains. One lacks the proteases that activate vacuolar
enzymes and contains only the catalytically inactive form of
Pho8p (proALP). The other strain has vacuolar proteases but is
deleted for the PHO8 gene. Fusion allows the proteases to gain
access to the inactive proALP and form active ALP. This assay
has the intrinsic limitation of sensitivity to any reagent that
inhibits ALP activity, the formation of active ALP, or vacuolar
proteases. We have therefore developed a complementary fu-
sion (content mixing) assay that does not require ALP or
proteases. This assay, based on the studies of Blau and colleagues
(10), uses vacuoles from two yeast strains (Fig. 1A). One contains
a chimeric protein of three parts: a fragment of carboxypeptidase
Y (CPY) specifying vacuole targeting (11), the 197 fragment of
the E. coli TEM-1 -lactamase, and the leucine zipper helix from
c-Jun (-Jun). The other carries a fusion protein of the same
domain of CPY, the 198 fragment of -lactamase, and the
leucine zipper helix from c-Fos (Fos-). Although neither
population of vacuoles [supporting information (SI) Fig. 5A] has
-lactamase activity (Fig. 1B, diamonds and squares), fusion
allows luminal protein mixing and rapid heterodimerization of
Fos and Jun helices, which brings the 197 and 198 fragments
together to reconstitute -lactamase activity (Fig. 1B, circles).
This assay (hereafter termed the -lactamase assay) comple-
ments the ALP fusion assay: (i) No orthologs of -lactamase
have been found in eukaryotes, including Saccharomyces cerevi-
siae, and thus the assay may avoid background activities. (ii)
Yeast vacuolar proteases can be released by lysis during in vitro
incubations and interfere with biochemical analysis. The -
lactamase assay uses only protease-deficient vacuoles. (iii) Al-
though phosphorylation and proteolysis can regulate trafficking,
phosphatase or protease inhibitors may inhibit the ALP assay
itself. The -lactamase fusion assay allows facile study of the
roles of phosphorylation or proteolysis in vacuole fusion. The
-lactamase and ALP assays measure luminal compartment
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mixing; each will be sensitive to inhibitors of fusion or of the
maturation or catalytic activity of its respective reporter enzyme.
To determine whether the -lactamase assay monitors Rab-
and SNARE-dependent vacuole fusion, we compared the effects
of known fusion inhibitors on the -lactamase and ALP assays
(Fig. 1C). Expression of the vacuole-targeted -Jun or Fos-
helical domains per se did not affect fusion, because vacuoles
from BJ3505--Jun or BJ3505-Fos- fused with DKY6281 vacu-
oles just as well as BJ3505 vacuoles (data not shown). Fusion in
both assays requires ATP and was blocked by priming inhibitors
such as antibodies to Sec17p or Sec18p, docking inhibitors such
antibodies to Vam3p or Vps33p, and lipid modifiers such as the
MED peptide that binds to phosphoinositides and the PLC
inhibitor U73122. Thus the -lactamase assay measures authen-
tic vacuole fusion. However, microcystin-LR (MCLR) and the
nonhydrolyzable GTP analogue GTPS, previously reported as
fusion reaction inhibitors (12, 13), showed different inhibitory
effects (Fig. 1 D and E). The -lactamase assay was less sensitive
to MCLR or GTPS than the ALP assay. Neither MCLR nor
GTPS alone increases -lactamase activity in a fusion-
independent manner, as the development of -lactamase activity
seen with 5 mM GTPS or 50 M MCLR is fully sensitive to
antibodies to Sec17p. The formation of -lactamase activity in
mixed detergent lysates of BJ3505--Jun or BJ3505-Fos- vacu-
oles is little affected by 5 mM GTPS or 100 M MCLR (see SI
Fig. 5C). MCLR prevents the development of active ALP in
mixed detergent lysates of BJ3505 and DKY6281 vacuoles (SI
Fig. 6A, triangles) even though it permits substantial proteolytic
formation of ALP from pro-ALP with intact vacuoles, a hall-
mark of fusion (SI Fig. 6B, lane 6). Thus, MCLR has greater
potency to inhibit the ALP assay than to prevent in vitro vacuole
fusion. Because higher concentrations of GTPS showed some
inhibition of the -lactamase assay (Fig. 1D), we further ex-
plored GTPS inhibition. Vacuoles from BJ3505 or DKY6281
were solubilized in Triton X-100, incubated separately in the
absence or presence of 5 mM GTPS on ice, and, after 20 min,
mixed and incubated at 27°C. GTPS (5 mM) partially ( 50%)
blocked the proteolytic cleavage of pro-ALP in detergent (SI Fig.
6B, lane 5 vs. lane 4) and completely prevented the development
of ALP activity (SI Fig. 6A, squares). The slow rate of pro-ALP
maturation in this experiment likely reflects the large dilution of
the proteases upon lysis as compared with their high concen-
trations within intact vacuoles. Thus GTPS inhibits pro-ALP
cleavage or ALP activation more than it inhibits fusion per se. To
further explore this, fusion reactions with intact vacuoles were
incubated for 90 min under low Mg2 conditions, where the ALP
assay is more sensitive to GTPS, and were assayed for ALP ac-
tivity (SI Fig. 6D) or for the proteolytic maturation of pro-ALP
by immunoblotting (SI Fig. 6 C and D). High concentrations of
GTPS prevent the proteolytic maturation of pro-ALP. Al-
though 2 mM GTPS reduced the proteolytic maturation of
pro-ALP by only 15%, the ALP activity was reduced by 80% (SI
Fig. 6D). These data show that low concentrations of GTPS can
inhibit the ALP assay by preventing the development of the
active form of the enzyme; they do not distinguish whether
higher concentrations inhibit fusion or merely block the proteo-
lytic maturation of pro-Pho8p. We therefore examined the
effects of GTPS by measuring the fusion-dependent size in-
crease of vacuoles (Fig. 2). Vacuoles were incubated on ice or at
27°C, without inhibitor or with GTPS or Fab fragments of
antibody to Sec18p, and were then labeled with the lipophilic dye
MDY-64 and observed by fluorescence microscopy. Although
many large vacuoles were formed in a standard reaction (Fig.
2B), no large vacuoles were formed on ice (Fig. 2 A) or in
reactions with antibodies to Sec18p (Fig. 2C). As many large
vacuoles were seen in a reaction with 4 mM GTPS (Fig. 2D) as
in the reaction without inhibitor (Fig. 2B), although the devel-
opment of ALP activity was 80% inhibited (Fig. 2G). The
fusion-dependent size increase of vacuoles in the presence of 4
mM GTPS is indistinguishable from that of the reaction
without inhibitors (Fig. 2F). Vacuole clustering and fusion began
to be inhibited by 5 mM GTPS (Fig. 2E). Large vacuoles are
a particularly clear sign of vacuole fusion (Fig. 2F). Whereas 86
vacuoles acquired 60 m2 surface area through fusion in a
Fig. 1. A vacuole fusion assay. (A) An in vitro vacuole fusion assay based on
complementary reconstitution of -lactamase. (B) Fusion-dependent -
lactamase activity formation over the 90-min time course. BJ3505-Fos- vacu-
oles, BJ3505--Jun vacuoles, or both were incubated at 27°C in fusion reac-
tions. A portion of reactions was transferred to ice at indicated times and
assayed for -lactamase activity. One unit (U) of the -lactamase activity is
defined as 1 nmol of hydrolyzed nitrocefin per min from 12 g of vacuole
protein. (C) Comparison between the -lactamase (black bars) and ALP (gray
bars) fusion assays. Fusion reactions (see Materials and Methods) were incu-
bated for 90 min on ice or at 27°C with indicated inhibitors. One reaction
lacked ATP. Values were normalized to the reactions without inhibitors
(3.78  0.65 units for the ALP assay; 1.76  0.45 units for the -lactamase
assay). Data represent mean  SEM (n  3). Inhibitors concentrations: affinity-
purified anti-Sec17p (153 nM), affinity-purified anti-Sec18p (142 nM), anti-
Vam3p IgG (444 nM), affinity-purified anti-Vps33p (155 nM), MED (10 M),
and U73122 (60 M). (D and E) The -lactamase fusion assay is less sensitive to
microcystin-LR (MCLR) and GTPS than the ALP assay. The -lactamase (gray
bars) and the ALP (black bars) fusion assays were performed in the presence of
increasing concentrations of GTPS (D) or MCLR (E) and antibodies to Sec17p
where indicated. Values were normalized to the reactions without inhibitors
(4.6  0.38 units for the ALP assay; 1.74  0.27 units for the -lactamase assay).
Data represent mean  SEM (n  3).








standard reaction of 772 scored (11%), and the same proportion,
118 of 1,190 scored (10%), acquired this size during incubation
with 4 mM GTPS, none acquired this size among either the 626
scored that had been incubated on ice without ATP or from the
1,127 scored that had been incubated with anti-Sec18 Fab. Thus,
although high concentrations of GTPS can inhibit fusion,
GTPS inhibition of the formation of active ALP is not a reliable
indicator of fusion inhibition.
To assay lipid mixing between fusing vacuoles, vacuoles were
labeled with self-quenching concentrations of octadecyl rhoda-
mine B (R18). Fusion of R18-labeled donor vacuoles with
unlabeled acceptor vacuoles permits dequenching through dilu-
tion of R18, as reported for rhodamine-phosphatidylethano-
lamine (PE) labeled vacuoles (9, 14). The increase in R18
fluorescence required unlabeled acceptor vacuoles (Fig. 3A,
filled vs. open circles), was accelerated by recombinant Vam7p
(open squares) or Sec18p (filled diamonds) and was blocked by
priming inhibitors such as antibodies to Sec17p or Sec18p, Rab
inhibitors including antibodies to Ypt7p and Gdi1p/Gyp1–46p,
SNARE inhibitors such as a mixture of three soluble domains of
vacuolar Q-SNAREs (15) and antibodies to Vam3p or Nyv1p or
the phosphoinositide ligand MED, all of which inhibited the
fusion in these same incubations (Fig. 3B). R18 has been
extensively used in HA protein-mediated hemifusion studies
(3–5, 16, 17). Because R18-dequenching during vacuole fusion
requires unlabeled acceptor vacuoles, is sensitive to known
fusion inhibitors, and can be stimulated by known fusion factors,
it represents the authentic fusion pathway rather than R18
translocation (18) or fusion-independent R18 transfer. We com-
pared the two content mixing assays, each coupled with the R18
dequenching assay, in the presence of GTPS (Fig. 3 C and D).
Low concentrations of GTPS allowed or even stimulated lipid
mixing (Fig. 3C, squares) while preventing the development of
active ALP (circles), as reported (9). In contrast, when we
assayed lipid and content mixing simultaneously by incubating
R18-labeled BJ3505 vacuoles that contain Fos- with unlabeled
BJ3505 vacuoles that contain -Jun (Fig. 3D), GTPS showed
only modest and similar inhibition of both lipid mixing and
content mixing. Differences in dequenching between these
experiments (Fig. 3 C and D) may reflect that vacuoles from
DKY6281 are only present in the ALP assay. We therefore
sought other means of resolving the late stages of fusion.
To examine late reaction stages, docking can be synchronized.
A portion of the membrane-anchored vacuole SNAREs is
unpaired and ready to pair in trans, whereas Vam7p, which lacks
Fig. 2. GTPS allows fusion but prevents pro-ALP activation. Fusion reactions
were performed under standard conditions but with 10 g of vacuoles. After
90 min, aliquots were stained with 3.3 M MDY-64 for fluorescent microscopy
(A–F) or assayed for ALP activity (G). Images were acquired and analyzed by
using ImageJ 1.36b and JMP 5.0.1a (SAS Institute). Vacuole diameters were
measured from micrographs taken from random fields, and the surface areas
of individual vacuoles were plotted as distribution histograms (F). A repre-
sentative field for each condition is shown (Scale bars, 20 m).
Fig. 3. The R18-dequenching lipid mixing assay. (A) Vacuoles were labeled
with R18, mixed with unlabeled vacuoles in lipid mixing assay reactions
containing anti-Sec17p (154 nM), anti-Sec18p (142 nM), anti-Ypt7p (167 nM),
Gdi1p (1.2 M)/Gyp1–46p (5 M), anti-Vam3p (444 nM), anti-Nyv1p (261 nM),
MED (10 M), 3sQ-SNARE (2 M), recombinant Sec18p (63 nM), rVam7p (40
nM), or buffer only (No addition), and lipid mixing was monitored at 27°C. One
reaction did not receive unlabeled acceptor vacuoles (open circles). (B) After
90 min, ALP activity was measured. (C and D) Vacuoles isolated from BJ3505-
Fos- were labeled with R18, reisolated, and added to lipid mixing assay
reactions containing unlabeled DKY6281 vacuoles (C) or unlabeled vacuoles
from BJ3505--Jun (D). Lipid mixing (squares) was monitored by R18 de-
quenching under low Mg2 condition at 27°C for 90 min with the indicated
concentrations of GTPS. After 90 min, the reactions were assayed for ALP
activity (C; circles) or -lactamase activity (D; circles). Values obtained without
inhibitors [2.31  0.46 units for the ALP assay coupled with the R18 assay
(F90min /FTX100  0.102  0.047); 1.53  0.07 units for the -lactamase assay
coupled with the R18 assay (F90min /FTX100  0.201  0.023)] were used as the
100% reference. Data represent mean  SEM (n  3).
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a transmembrane anchor, is present only on isolated vacuoles in
cis-SNARE complexes (19). Its liberation by Sec17p/18p/ATP
allows trans-SNARE complex assembly. By incubating vacuoles
with anti-Sec17p antibodies (20, 21), tethering can occur, but
trans-SNARE pairing is prevented by the absence of free
Vam7p. Addition of soluble recombinant SNARE Vam7p (22)
permits synchronous SNARE pairing (15). The reaction rapidly
acquires insensitivity to Vam3p antibody (half-time 1 min),
whereas content mixing occurs relatively slowly, with a half-time
of 15 min (20, 21). Strikingly, after rVam7p addition the R18
dequenching (Fig. 4A, squares) has a half-time of 2 min,
concurrent with or shortly after resistance to anti-Vam3p (dia-
monds) but well before content mixing (circles). Thus, lipid
mixing occurs very soon after SNARE pairing but well before
content mixing. We have recently shown that the phosphoino-
sitide ligand MED prevents vacuole fusion, whereas it allows the
formation of trans-SNARE complexes (23). We therefore as-
sayed trans-SNARE complex formation (23), lipid mixing, and
fusion from the same samples of mixed R18-labeled and unla-
beled vacuoles. MED permits trans-SNARE pairing (Fig. 4D)
but blocks lipid mixing (Fig. 4B) or fusion (Fig. 4C), suggesting
that phosphoinositides are required for the rapid lipid mixing
after trans-SNARE assembly.
The substantial lag in developing ALP activity could have
been due to a slow proteolytic maturation of ALP. This is
however unlikely: (i) Although the vacuolar protease Prb1p is
largely responsible for ALP maturation, Prb1p overproduction
has no effect on the kinetics of fusion-dependent ALP matura-
tion (20), showing that Prb1p had not been limiting to matura-
tion. (ii) Mature ALP appears in vivo with a half-life of 6 min
(24), which includes its synthesis and transport through the
endoplasmic reticulum and Golgi to the vacuole; thus the
proteolytic maturation of pro-ALP in the vacuole takes much
less than 6 min. (iii) The half-time of -lactamase formation
from its two halves in mixed detergent extracts of 0.2-mg
vacuoles/ml from BJ3505--Jun and BJ3505-Fos- is 30 min
(SI Fig. 5B), and with 2 mg/ml vacuole extracts the half-time for
-lactamase formation drops to 4 min (SI Fig. 5D); even these
extracts have far lower concentrations of the two halves of
-lactamase than the intact and fused vacuoles. The kinetics of
content mixing (fusion) in the ALP assay (SI Fig. 5E, open
symbols) and -lactamase assay (SI Fig. 5E, filled symbols) are
identical, indicating that there is a true kinetic interval between
the SNARE-pairing and lipid-mixing steps of docking and the
final aqueous compartment mixing of fusion. This kinetic inter-
val may reflect a lipidic, possibly hemifusion, intermediate
during vacuole fusion, although we do not have direct evidence
for hemifusion.
Discussion
We describe an assay that exploits the fusion-dependent recon-
stitution of -lactamase activity from two complementary frag-
ments. This complements the standard in vitro vacuole fusion
assay of proteolytic activation of pro-Pho8p. The assay we
describe has allowed a fresh evaluation of whether lipid mixing
occurs at a distinct stage of fusion, such as a hemifusion
intermediate, which precedes the final mixing of the aqueous
vacuole lumens. Hemifusion was proposed as an intermediate
during vacuole fusion based on the observation that GTPS
permitted lipid mixing but blocked the formation of active ALP
(9). We now show that GTPS is a more potent inhibitor of the
formation of active ALP than of fusion per se, yet our findings
are consistent with a hemifusion mechanism, as previously
suggested (9). This sensitivity to GTPS also vitiates our earlier
use of this compound (25) in studies of the multiplicity of
GTPases that regulate vacuole fusion.
Hemifusion can be induced in a minimal SNARE-driven
liposome fusion system by low levels of wild-type SNARE
proteins or by mutant SNARE proteins that have partial TMDs
that only span the outer bilayer leaflet (6). A hemifusion
intermediate was also detected at the single-liposome level by
monitoring FRET between membrane-bound fluorophores in
single fusion events between pairs of SNARE-reconstituted
liposomes (7), and in flipped SNARE-mediated cell-cell fusion
(8). These results suggest that the SNARE-dependent fusion of
intracellular membranes like yeast vacuoles might also proceed
through a hemifusion intermediate. We had previously reported
that a reaction stage between docking and content mixing was
sensitive to certain lipid ligands (19) and that lipid rearrange-
ment is required after trans-SNARE complex formation before
fusion (23), indicative of a lipidic intermediate. We now show
that there is a substantial kinetic separation between lipid mixing
and content mixing by using a R18-dequenching lipid-mixing
assay and two distinct content-mixing assays.
What molecular models could encompass our current knowl-
edge about vacuole lipid mixing and fusion? We have shown that
proteins and lipids that are required for fusion become enriched
at a vertex ring microdomain of docked vacuoles (26, 27). Fusion
around this ring leaves membrane vesicles within the vacuole
(27). This intralumenal membrane is not easily explained by a
hemifusion model (SI Fig. 7A) in which an intermediate with a
micron-sized hemifusion diaphragm proceeds to full fusion
through a single fusion pore. We therefore propose a working
model of vertex ring hemifusion to explain how a hemifusion
intermediate can promote fusion around a vertex ring (SI Fig.
7B). Proteins and lipids that regulate docking and fusion accu-
mulate at the vertex ring. The formation of trans-SNARE
complexes around the ring may allow rapid lipid mixing between
outer leaflets from two apposed bilayers (based on the similar
kinetics of trans-SNARE complex formation and lipid mixing;
Fig. 4A), generating a ring-shaped hemifusion diaphragm or a
ring of point-hemifusions. This vertex ring hemifusion model fits
better with key observations about vacuole fusion than a model
(SI Fig. 7A) in which hemifusion originates at a single point on
the apposed membrane surfaces (17). Three salient features of
the latter model (SI Fig. 7A) are: (i) the absence of transmem-
brane proteins in the hemifusion diaphragm, (ii) the absence of
external (cytoplasmic) leaflet lipids (SI Fig. 7A, green and red)
in the hemifusion diaphragm, and (iii) the absence of a luminal
vesicle after expansion of the fusion pore. Each of these features
is difficult to reconcile with the observed facts of vacuole fusion:
(i) the boundary membranes of docked vacuoles have a full
complement of membrane proteins (27), and thus could not
simply represent a large hemifusion diaphragm. (ii) FM4–64 and
MDY-64, which label the external leaflet of vacuoles, are found
with equal abundance in the boundary membrane microdomain
as in the outer membrane (27). (iii) Fusion of docked vacuoles
generates luminal vesicles bearing vacuolar lipids and integral
membrane proteins (27). The vertex ring hemifusion model
accommodates each of these observations; the boundary mem-
brane consists of two complete bilayers and thus has integral
membrane proteins and both bilayer leaflets. Current data do
not distinguish between vertex ring hemifusion and a ring of
point-hemifusion events. Resolution of the hemifused state by
invasion of lipids, as shown in SI Fig. 7B (blue arrows in the
middle panel), would generate luminal vesicles. Although this
model may lead to further experiments, we caution that none of
our results directly show hemifusion.
Classical hemifusion may represent a limiting condition of
vertex ring hemifusion where the area of the apposed, boundary
membrane approaches a point. Fusion studies of membranes
bearing the HA protein (5) or SNAREs (28, 29) have suggested
a ring of several copies of each protein around the nascent pore.
Below a certain minimal size of the boundary membrane, a
luminal vesicle would not form and point-hemifusion would be
expected.









Plasmids, Yeast Strains, and Reagents. The plasmid pYJ406 was
generated by introducing the 720-bp upstream region and the
300-bp downstream region of the ADH1 gene into XhoI/HindIII
and SacII/SacI sites of the pRS406 plasmid. The pYJ406-CPY50
plasmid was constructed by ligating the first 50 codons of CPY
into pYJ406, immediately 3 of the ADH1 promoter. Because the
ADH1 promoter is constitutively strong, and the N-terminal 50
aa of CPY can direct delivery of a fused protein to the vacuolar
lumen (11), as confirmed with CPY50-YFP (data not shown),
the resulting plasmid pYJ406-CPY50 allowed an overexpressed
protein to be targeted to the vacuolar lumen. Plasmids Fos-
GS-W and A-GS-Jun (10), generous gifts from Helen Blau
(Stanford University, Stanford, CA), were used to amplify
regions encoding a fusion protein of c-Fos -helix and 
fragment of E. coli TEM1 -lactamase and a chimera of 
fragment of -lactamase and c-Jun -helix, respectively. The
PCR products were subcloned into pYJ406-CPY50 by using
BamHI and SacII sites, generating pYJ406-Fos- and pYJ406-
-Jun. Because the PCR product from A-GS-Jun has an internal
BamHI site, BglII was used instead. Plasmids pYJ404-Fos- and
pYJ404--Jun were also generated from pRS404 as above.
Vacuoles from BJ3505 (Mat ura3–52 trp1-101 his3-200
lys2-801 gal2 (gal3) can1 prb1-1.6R pep4::HIS3) (30) and
DKY6281 (Mat ura3-52 leu2-3,112 trp1-901 his3-200 lys2–
801 suc2-9 pho8::TRP1) (13) were used for ALP fusion assays.
To generate strains with Fos- and -Jun in their vacuolar
lumen, BJ3505 was transformed with pYJ406-Fos- and
pYJ404-Fos- or pYJ406--Jun and pYJ404--Jun, generating
BJ3505-Fos- or BJ3505--Jun. The resulting BJ3505-Fos- or
BJ3505--Jun therefore bears two copies of Fos- or -Jun,
respectively. This double gene dosage yields a 2-fold-more-
sensitive fusion assay. The vacuolar expression of the -
lactamase fragments was confirmed by immunoblotting (SI Fig.
5A). The -lactamase substrate nitrocefin (Calbiochem, San
Diego, CA) was dissolved in DMSO. GTPS was purchased
(Roche, Indianapolis, IN) as a 100 mM solution. Microcystin-LR
(Alexis Biochemicals, San Diego, CA) and octadecyl rhodamine
B (R18) (Molecular Probes, Eugene, OR) were dissolved in
ethanol. MDY-64 (Molecular Probes) and the phospholipase C
(PLC) inhibitor U73122 (Calbiochem) were dissolved in DMSO.
Rabbit polyclonal antibody to -lactamase was purchased from
Chemicon International (Temecula, CA).
Vacuole Isolation and in Vitro ALP Fusion Assay. Vacuole concen-
trations were expressed as protein content, determined by
Bradford with albumin standards. For the ALP assay, reactions
(30 l) contained 3 g of vacuoles lacking the proteases Pep4p
and Prb1p, 3 g of vacuoles from cells without Pho8p, reaction
buffer [125 mM KCl/5 mM MgCl2/20 mM Pipes-KOH (pH
6.8)/200 mM sorbitol], 1 mM ATP, 40 mM creatine phosphate,
0.5 mg/ml creatine kinase, and 10 M CoA (13). For experiments
in the ‘‘low Mg2’’ condition, fusion reactions contained 0.25
mg/ml creatine kinase, 20 mM creatine phosphate, 0.5 mM ATP,
and 0.5 mM MgCl2 in reaction buffer [110 mM KCl/0.3 mM
MnCl2/200 mM sorbitol/10 mM Pipes/KOH (pH 6.8)] as de-
scribed (9). After 90 min at 27°C, fusion was measured by
assaying ALP.
The -Lactamase Vacuole Fusion Assay. Vacuoles containing the
chimeric protein Fos- or -Jun were isolated from BJ3505-
Fig. 4. Kinetics of lipid and content mixing. (A) Kinetic separation of SNARE
complex assembly and lipid mixing from content mixing. ALP fusion reactions (1
g of R18-labeled BJ3505 vacuoles and 5 g of unlabeled DKY6281 vacuoles)
contained affinity-purified anti-Sec17p (154 nM). Recombinant Vam7p (1 M)
was added after 20 min. A portion of each reaction was transferred to a micro-
plate fluorometer and monitored for R18 dequenching at 27°C for 64 min. The
remainder received anti-Vam3p IgG or were placed on ice at indicated times
(	-0.5, 0.5, 1, 2, 4, 8, 16, 32, 48, or 64 min). ALP activity was measured after 64 min.
Fusion values were normalized to reactions that were placed on ice at 64 min
(3.48  0.3). The relative fluorescence change F64min/FTX100 (see Materials and
Methods) at 64 min (0.124  0.002) was the 100% reference for lipid mixing. Data
represent mean  SEM (n  3). (B–D) MED allows trans-SNARE complex assembly
but blocks lipid mixing and content mixing. Vacuoles isolated from the BJ3505-
CBP-Vam3p nyv1 yeast strain were labeled with 150 M R18, reisolated, and
addedtolipidmixingassayreactionscontainingunlabeledvacuoles isolatedfrom
BJ3505-CBP-Vam3p nyv1 and DKY6281 yeast strains. The lipid mixing assay
reactions (480 l) contain 10.7 g of R18-labeled vacuoles and 85.3 g of unla-
beled vacuoles. Lipid mixing was monitored at 27°C without inhibitors, with
Gdi1p (1.2 M)/Gyp1–46p (5 M)orwithMED(10 M)(B).After60min,aportion
of reactions (30 l) was withdrawn to assay ALP activity (C). Data represent
mean  SEM (n  3). The remaining reactions (450 l) were subjected to assay of
trans-SNARE complexes (see Materials and Methods). The transassociation of
CBP-Vam3p from the BJ3505-CBP-Vam3p nyv1 vacuoles with Nyv1p from the
DKY6281 vacuoles is shown (D).
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Fos- or BJ3505--Jun (13). Standard -lactamase fusion reac-
tions (60 l) contained 6 g of vacuoles containing the fusion
protein Fos-, 6 g of vacuoles with -Jun, the same reaction
buffer, ATP, creatine phosphate, creatine kinase, and CoA as for
the ALP fusion assay, and 11 M recombinant GST-Fos protein
(to reduce any background signal due to lysis). After 90 min at
27°C, the reactions were transferred to ice, 140 l of ice-cold
nitrocefin developing buffer [100 mM NaPi (pH 7.0)/150 M
nitrocefin/0.2% (vol/vol) Triton X-100] was added, and the
mixture was placed in a 96-well clear plate with flat bottom
(Corning Life Sciences, Corning, NY). Nitrocefin hydrolysis was
measured by absorbance at 492 nm every 15 seconds for 5–10
min at 30°C with a VERSAmax microplate reader (Molecular
Devices, Sunnyvale, CA); the absorbance increased linearly
during this time interval, and the slope was determined. A blank
reference well contained 150 l from a sample containing 6 g
of Fos- vacuole, 6 g of -Jun vacuole, 11 M recombinant
GST-Fos protein, and 140 l of nitrocefin developing buffer in
200 l. One fusion unit of the -lactamase fusion assay is defined
as 1 nmol of hydrolyzed nitrocefin per minute from 12 g of
vacuole protein. One hundred nmol of hydrolyzed nitrocefin
equals 0.53 of OD492 (31).
Lipid Mixing Assay Using Octadecyl Rhodamine B (R18) Dequenching.
Freshly prepared BJ3505 vacuoles (300 g) were suspended in
400 l of PS buffer containing 150 M R18 in an amber
microcentrifuge tube. After mixing gently with a wide-bore
pipette tip, the mixture was incubated (10 min, 4°C) with rocking.
PS buffer (600 l) with 15% (wt/vol) Ficoll was added, and the
suspension was transferred to a Polyallomer tube (11 
 60 mm)
(Beckman, Fullerton, CA), overlaid with 1.2 ml of PS buffer with
8% (wt/vol) Ficoll, 1.2 ml of PS buffer with 4% (wt/vol) Ficoll,
and 0.5 ml of PS buffer without Ficoll, centrifuged [20 min, 4°C,
105,200 
 g, SW 60 Ti (Beckman)], and labeled vacuoles were
recovered from the 0%/4%-Ficoll interface by using a wide-bore
pipette tip. Standard lipid mixing assays (180 l) contained 4 g
of R18-labeled vacuoles, 32 g of unlabeled vacuoles, and the
same reaction buffer, ATP, creatine phosphate, creatine kinase,
and CoA as in fusion assays. Reaction mixtures (150 l) were
transferred to a 96-well f lat-bottom assay plate with nonbinding
surface (Corning). Fluorescence change was measured with a
SpectraMax GeminiXPS fluorescent plate reader (Molecular
Devices) at 27°C, 560-nm excitation and 590-nm emission as
described (9) with minor modifications. Measurements were
taken every 2–3 min for 60–90 min, yielding fluorescence values
at the onset (F0) and during the reaction (Ft). The final 10
measurements of a sample containing 0.33% (vol/vol) Triton
X-100 was averaged and used as a value for the fluorescence
after infinite dilution (FTX100). The relative total f luorescence
change Ft /FTX100  (Ft 	 F0)/FTX100 was calculated. Fusion-
dependent fluorescence change was calculated by subtracting
fusion-independent fluorescence change values represented by a
sample containing only labeled donor vacuoles from total f lu-
orescence change values.
Assay of trans-SNARE Complexes. Assays of trans-SNARE com-
plexes were performed as described (23) with modifications.
Briefly, standard trans-SNARE and fusion assays (16
) con-
tained 48 g of vacuoles isolated from the BJ3505-CBP-Vam3p
nyv1 yeast strain and 48 g of vacuoles isolated from DKY6281
yeast strain. After 60 min, reactions were placed on ice (5 min).
From each 16
 reaction, 30 l was withdrawn to assay Pho8p
maturation, and the rest (450 l) was centrifuged (11,000 
 g, 5
min, 4°C). The supernatant was removed, and the sedimented
vacuoles were overlaid with ice-cold solubilization buffer [200 l
of 20 mM TrisCl (pH 7.5)/150 mM NaCl/1 mM MgCl2/0.5%
Nonidet P-40 Alternative (Calbiochem)/10% glycerol/1
 pro-
tease inhibitor mixture (0.46 g/ml leupeptin/3.5 g/ml pepstatin/
2.4 g/ml pefabloc-SC/1 mM PMSF], resuspended on ice, and
solubilization buffer was added to a final volume of 600 l. The
extracts were mixed on a nutator rocker (20 min, 4°C), and the
detergent insoluble material was removed by centrifugation
(16,000 
 g, 20 min, 4°C). Ten percent of the extract was
removed for a total sample, and the remaining extract was
brought to 2 mM CaCl2. The CBP-Vam3p was recovered with
calmodulin affinity beads (50 l per 600 l of extract; Strat-
agene, La Jolla, CA) on a nutator at 4°C overnight. Beads were
collected by brief centrifugation (4,000 
 g, 2 min, 4°C) and
suspended five times with the solubilization buffer, followed by
bead sedimentation. Bound proteins were eluted by boiling
beads in SDS sample buffer containing 5 mM EGTA (94°C, 5
min) for SDS/PAGE analysis and immunoblotting.
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